Alpha Cognition (ACOG) vs Adagene (ADAG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Adagene (ADAG) has outperformed Alpha Cognition (ACOG) over the past year, gaining 41.2% versus a gain of 23.0%. Alpha Cognition is the larger company by market cap ($194.9 million vs $183.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACOG | ADAG |
|---|---|---|
| Share price | $8.95 | $2.74 |
| Market cap | $194.91M | $183.64M |
| 1-day change | -1.00% | -2.67% |
| YTD return | +39.08% | +48.68% |
| 1-year return | +22.99% | +41.21% |
| 5-year return | — | -75.98% |
| EPS (TTM) | $-1.32 | $-0.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.14 | $4.85 |
| 52-week low | $4.50 | $1.30 |
| Distance from 52-week high | -11.74% | -43.61% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +101.12% | +262.34% |
| Average volume | 124.69K | 245.22K |
| Shares outstanding | 21.78M | 67.14M |
| Employees | 71 | 128 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADAG has outperformed ACOG by 18.2 percentage points over the past year.
- The two companies sit in different sectors: Alpha Cognition in Healthcare and Adagene in Health Care.
About Alpha Cognition
ACOG stock →Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease.
Healthcare · Biotechnology · 71 employees
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
ACOG vs ADAG FAQ
Which is bigger, Alpha Cognition or Adagene?
Alpha Cognition (ACOG) is larger, with a market capitalization of $194.91M compared with $183.64M for Adagene (ADAG).
Which stock has performed better over the past year, ACOG or ADAG?
ADAG returned +41.21% over the past 12 months, compared with +22.99% for ACOG (price return, excluding dividends). Past performance does not predict future results.
Are Alpha Cognition and Adagene in the same industry?
No. Alpha Cognition is in the Healthcare sector, while Adagene is in Health Care.